SOLV:NYE-Solventum Corp. (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 74.5

Change

+0.52 (+0.70)%

Market Cap

USD 13.01B

Volume

0.50M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-20 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
DOCS Doximity Inc

-2.63 (-3.51%)

USD 11.03B
WEAV Weave Communications Inc

-2.63 (-15.57%)

USD 1.25B
MPLN MultiPlan Corporation

-0.19 (-0.64%)

USD 0.30B
AMWL American Well Corp

-0.32 (-2.65%)

USD 0.18B
OWLT Owlet Inc

+0.26 (+5.24%)

USD 0.08B
PHR Phreesia Inc

-0.24 (-0.84%)

N/A
VEEV Veeva Systems Inc Class A

-2.95 (-1.29%)

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

-0.28 (-2.61%)

N/A
TDOC Teladoc Inc

-1.18 (-9.30%)

N/A

ETFs Containing SOLV

CSD Invesco S&P Spin-Off ETF 0.00 % 1.16 %

-2.90 (-3.40%)

N/A
CSD Invesco S&P Spin-Off ETF 0.00 % 0.61 %

-2.90 (-3.40%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.78% 55% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.78% 55% F 90% A-
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 13.01B 100% F 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.